ClinicalTrials.gg
TerminatedNCT00853762ATAMS extUpdated Mar 20, 2017Results posted

Atacicept in Multiple Sclerosis Extension Study, Phase II

A Phase 2 interventional study of Atacicept 25 mg and Atacicept 75 mg in Relapsing Multiple Sclerosis, sponsored by EMD Serono. Terminated at 48 sites in 17 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2017-03-20.

Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
EMD Serono voluntarily decided to terminate this trial after observing increased MS disease activity in trial 28063 ATAMS \[Please refer to ATAMS\]

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 71 studies in Multiple Sclerosis by Merck KGaA, Darmstadt, Germany — none open to participants now, 1 under way, none of them phase 3. Multiple Sclerosis · Merck KGaA, Darmstadt, Germany.

Enrollment
27th of 33
74 · median 219
Started
2009
with 6 others
Phase 2
9 of 71
none open now
Registered
13th of 71
by date

Among the 71 studies in Multiple Sclerosis by Merck KGaA, Darmstadt, Germany, this one is the 27th largest by enrollment of the 33 interventional ones that give a count, is one of 7 that started in 2009, is one of 9 in phase 2, and was the 13th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 664 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

None of the 71 studies in Multiple Sclerosis by Merck KGaA, Darmstadt, Germany is open now. The open studies under Multiple Sclerosis, anywhere →

Who these studies take

Of the 432 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 213 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 71 studies in Multiple Sclerosis by Merck KGaA, Darmstadt, Germany as a file.
02

Study summary

This study (28851) is a long-term follow-up study of subjects enrolled in ATAMS study 28063 (NCT00642902). The aim of this study is to monitor the safety and tolerability of atacicept administered for up to 5 years to subjects with relapsing multiple sclerosis (RMS).

This extension study consists of two parts. Part A will be double blind and Part B will be open label. During Part A, subjects initially randomized to atacicept will continue to receive the atacicept dose to which they have been randomized in study 28063 (ATAMS) once a week subcutaneously (under the skin). Subjects randomized to placebo in ATAMS will receive atacicept at 150 mg once a week subcutaneously during Part A. Once the results of ATAMS are available and the atacicept dose with the best benefit / risk ratio has been identified, all subjects will be switched to this dose and will continue the extension study open-label (Part B). Throughout the study, subjects and investigators will remain blinded with respect to initial and part A treatment allocation/dose.

03

Conditions studied

  • Relapsing Multiple Sclerosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participation in study 28063.
  • Completion of Week 36 visit of the core study 28063.
  • Willingness and ability to comply with study procedures for the duration of the study.
  • Voluntary provision of written (including, for the USA, subject authorization under the Health Insurance Portability and Accountability Act (HIPAA)), given before any study-related procedure that is not part of normal medical care and with the understanding that the subject may withdraw consent at any time without prejudice to his or her future medical care.

Exclusion criteria

Exclusion Criteria:

  • Premature discontinuation of core study 28063.
  • Subjects who meet criteria listed below will receive IMP in study 28851:

    • Subjects who are eligible for participation in extension study 28851 but do not meet these criteria will not be treated with IMP but will undergo scheduled visits, irrespective of their treatment.
  • All subjects must satisfy the following criteria before Extension Study Day 1 (D1-EXT; defined as the first day of dosing in the extension study) to be eligible for treatment with IMP:

    • Eligibility for participation in extension study 28851.
    • For women of , a negative urine pregnancy test at eligibility assessment.
    • Female subjects of childbearing potential must be willing to avoid pregnancy by using an adequate method of for four (4) weeks before the first dose administered within the extension study, during the study and for twelve (12) weeks after the last dose of trial medication. Adequate contraception is defined as two barrier methods, or one barrier method with spermicide, or an intrauterine device, or use of a combined oral female hormonal contraceptive (or the definitions requested by health authorities and locally amended in the core study 28063). For the purposes of this trial, women of childbearing potential are defined as: "All female subjects after puberty unless they are for at least two years or are surgically sterile" (For Germany Only: Female subjects of childbearing potential must be willing to avoid pregnancy by using highly effective methods of contraception for approximately four (4) weeks prior to D1-EXT, during and for twelve (12) weeks after the last dose of trial medication. This requirement does not apply to surgically sterile subjects or to subjects who are postmenopausal for at least 2 years. Highly effective contraception is defined as any method or combination of methods which result in a low failure rate (i.e. less than (\<) 1% per year) when used consistently and correctly, such as implants, injectables, combined oral contraceptives, sexual abstinence, vasectomized partner, 2 barrier methods, or 1 barrier method with spermicide)
  • Willingness and ability to comply with study procedures for the duration of the study.
  • To be eligible for treatment with medicinal product (IMP) in study 28851, the subjects must not meet any of the following criteria:
  • Non-eligibility for participation in extension study 28851 (premature discontinuation of core study 28063).
  • Major protocol violation or non-compliance in the core study.
  • Use of prohibited immunomodulatory / therapies
  • Serum immunoglobulin G (IgG) level \<3 gram per liter (g/L) if the subject received atacicept in the core study, or serum IgG level \<6 g/L if the subject received placebo in the core study (to protect the blinding of the core study, the IgG level will be communicated to the treating physician only if it is too low for extension study participation and only after all Week 36 assessments performed within the core study have been completed).
  • Any condition, including laboratory findings that, in the opinion of the Investigator, constitutes a risk or a for participation in the extension study, or that could interfere with the study objectives, conduct or evaluation.
  • Known active acute or chronic infection, or any major episode of infection requiring hospitalization or treatment with parenteral anti-infectives.
  • Investigator judgement that treatment of the subject with atacicept in the extension study is not appropriate.
  • (AST), or alanine aminotransferase (ALT), or alkaline phosphatase (AP) level greater than (>)2.5 x (ULN), or total >1.5 x ULN at eligibility assessment.
  • Clinically significant abnormality in any hematological test (e.g. \<100 g/L (6.21 millimoles per liter [mmol/L]), white blood cells \<3 x 10\^9 per liter (/L), \<100 x 10\^9/L) at eligibility assessment.
  • Clinically significant abnormality on (ECG) performed at eligibility assessment.
  • Presence of uncontrolled or New York Health Association () class 3 or 4 congestive heart failure at Week 36 of the core study.
  • Moderate to severe renal impairment ( \<50 milliliter per minute (mL/min) according to Cockcroft-Gault equation).
  • Allergy or to gadolinium (Gd).
  • Allergy or hypersensitivity to atacicept or to any of the components of the formulated atacicept.
  • Diagnosis or family history of Creutzfeldt-Jakob disease (CJD).
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    Atacicept 25 mg (With Loading)

    Drug: Atacicept 25 mg

  • Experimental
    Atacicept 75 mg (With Loading)

    Drug: Atacicept 75 mg

  • Experimental
    Atacicept 150 mg (With Loading)

    Drug: Atacicept 150 mg

  • Experimental
    Atacicept 150 mg (Without Loading)

    Drug: Atacicept 150 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Injection Site Reactions, Infections, and Malignancies by Severity

    TEAEs were defined as AEs with a start date after or on the date of the first DB treatment injection in ATAMS Extension and that occurred anytime after treatment discontinuation, or up to the day before first Rebif® rescue medication injection in ATAMS Extension. A serious TEAE was an AE that resulted in any of the following: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. TEAE severity was graded as per Qualitative Toxicity Scale. Local injection site reactions (injection site: pain, redness, itching and swelling) throughout ATAMS Extension, starting after the first trial medication administration. If the subject experienced 1 or more of the above injection site symptoms, these were reported with the AE verbatim term "injection site reaction". For all randomized subjects, there was an option of rescue treatment with Rebif® for 1 year beginning with the first injection of Rebif®).

    Time frame: From the first dose of study drug administration up to Week 24

  2. Change From Baseline in Vital Signs: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

    Blood pressure (systolic and diastolic) was measured after at least 3 minutes resting, with the subject in the seated position.

    Time frame: Baseline, Week 2, 4, 8, 12, 16, 20, 24 and 36

  3. Change From Baseline in Vital Signs: Pulse Rate

    Time frame: Baseline, Week 2, 4, 8, 12, 16, 20, 24 and 36

  4. Change From Baseline in Vital Signs: Temperature

    Time frame: Baseline, Week 2, 4, 8, 12, 16, 20, 24 and 36

  5. Change From Baseline in Electrocardiogram (ECGs)

    Time frame: Baseline, Week 12 and 36

  6. Number of Subjects With Worsened Post Baseline Shift in Immunoglobulin A (IgA), IgG and IgM Levels

    Number of subjects with shifts from normal Grade (Grade 0) at Baseline to worse value at post-baseline (Grade 1 to Grade 4) according to the following criteria: IgA Grade 0: greater than or equal to (\>=) lower limit normal (LLN) 0.7 gram per liter (g/L); Grade 1: less than (\<) LLN - 0.5 g/L, Grade 2: \<0.5g/L -0.3 g/L, Grade 3: \<0.3 g/L -0.1 g/L, Grade 4: \< 0.1 g/L; IgG Grade 0: \>= LLN (7 g/L), Grade 1: \< LLN - 5 g/L, Grade 2: \<5g/L -4 g/L, Grade 3: \<4 g/L -3 g/L and Grade 4: \< 3 g/L; IgM Grade 0: \>= LLN (0.4 g/L), Grade 1: \< LLN - 0.3 g/L, Grade 2: \<0.3 g/L -0.2 g/L, Grade 3: \<0.2 g/L -0.1 g/L, and Grade 4: \< 0.1 g/L are presented in this outcome measure.

    Time frame: Baseline up to Week 36

  7. Number of Subjects With Positive Neutralizing Antibody (NAb)

    Time frame: Baseline, Week 12 and 36

Secondary outcomes

  1. Number of Subjects With Clinical Attacks/Relapses

    A clinical attack/relapse was defined as the fulfillment of all the following criteria: 1. Neurological abnormality, either newly appearing or re-appearing, with abnormality specified by both i) neurological abnormality separated by at least 30 days from onset of a preceding clinical event, and ii) neurological abnormality lasting for at least 24 hours. 2. Absence of fever or known infection (fever with temperature (axillary, orally, or intra-auriculary) \> 37.5°C/99.5 °Fahrenheit). 3. Objective neurological impairment, correlating with the subject's reported symptoms, defined as either i) increase in at least 1 of the functional systems of the Expanded Disability Status Scale (EDSS), or ii) increase of the total EDSS score. EDSS overall score ranging from 0 (normal) to 10 (death due to MS) was calculated.

    Time frame: Baseline up to Week 24

  2. Change From Baseline in Expanded Disability Status Scale (EDSS) Scores at Week 12

    EDSS is an ordinal scale in half-point increments that qualifies disability in participants with multiple sclerosis (MS). It assesses the 8 functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder, cerebral and other) as well as ambulation. EDSS overall score ranging from 0 (normal) to 10 (death due to MS) was calculated.

    Time frame: Baseline, Week 12

  3. Change in Multiple Sclerosis Functional Composite (MSFC) Score at Week 12

    The MSFC is a multidimensional clinical outcome measure which consists of three sub-tests; Timed 25-Foot Walk, 9-Hole Peg Test and Paced Auditory Serial Addition Test-3(PASAT-3). The Timed 25-Foot Walk is a quantitative measure of lower extremity function. The 9-Hole Peg Test is a quantitative measure of upper extremity (arm and hand) function. The PASAT is a measure of cognitive function that specifically assesses auditory information processing speed and flexibility, as well as calculation ability. Standardized results (Z-scores) of these sub-tests and the overall MSFC Z-score as an average of these three Z-scores was calculated. Higher Z-scores reflect better neurological function and a positive change from baseline indicates improvement. An increase in score indicates an improvement (range -3 to +3).

    Time frame: Week 12

  4. Magnetic Resonance Imaging (MRI) Parameters: Number of T1 Gadolinium (Gd)-Enhancing Lesions Per Subject

    Time frame: Baseline, Week 12 and 24

  5. Magnetic Resonance Imaging (MRI) Parameters: Volume of T2 Lesions (New or Enlarging T2 Lesions) Per Subject

    Time frame: Baseline, Week 12 and Week 24

  6. Concentrations of Free and Total Atacicept

    Time frame: Baseline and Week 12

  7. Free B-Lymphocyte Stimulator (BLyS) and Free A Proliferation-Inducing Ligand (APRIL) Serum Concentrations.

    Levels of free APRIL and free BLyS: Free APRIL serum samples were to be analyzed by using a validated enzyme-linked immunosorbent assay (ELISA) with limits of detection of 0.3125 nanogram per milliliter (ng/mL) for free APRIL and free BlyS serum samples were analysed using a validated ELISA with limits of detection of 1.56 ng/mL.

    Time frame: Baseline, Week 12 and 36

  8. Pharmacogenetics/Pharmacogenomics Analysis

    Gene expression profiling and gene polymorphism identification were to be used to identify putative markers for response to treatment. * Genome-wide gene polymorphism characterization by genome-wide scan. * Targeted gene polymorphism identification of B-Lymphocyte Stimulator (BLyS) , APRIL, (receptor for B cell activating factor of the tumor necrosis factor \[TNF\] family) BAFF-R, (Transmembrane Activator) TACI and (B Cell Maturation Antigen) BCMA and HLA-DRB1 by direct genotyping or sequencing .

    Time frame: Day 1 and Week 36

07

Results

Posted May 24, 2016
Limitations and caveats
Sponsor voluntarily decided to terminate this trial after observing increased MS disease activity in trial 28063 ATAMS.

Participant flow

First/last participant (informed consent): 03 March 2009/13 August 2009. Last participant completed: 09 September 2009.

Participant flow — Overall Study
MilestoneAtacicept 25 mg (With Loading)Atacicept 75 mg (With Loading)Atacicept 150 mg (With Loading)Atacicept 150 mg (Without Loading)
Started16191722
Completed0000
Not completed16191722
Withdrew: Premature termination16151421
Withdrew: Protocol violation0001
Withdrew: Withdrawal by subject0010
Withdrew: Other0200
Withdrew: Randomised but not treated0220

Outcome measures

PrimaryNumber of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Injection Site Reactions, Infections, and Malignancies by Severity

TEAEs were defined as AEs with a start date after or on the date of the first DB treatment injection in ATAMS Extension and that occurred anytime after treatment discontinuation, or up to the day before first Rebif® rescue medication injection in ATAMS Extension. A serious TEAE was an AE that resulted in any of the following: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. TEAE severity was graded as per Qualitative Toxicity Scale. Local injection site reactions (injection site: pain, redness, itching and swelling) throughout ATAMS Extension, starting after the first trial medication administration. If the subject experienced 1 or more of the above injection site symptoms, these were reported with the AE verbatim term "injection site reaction". For all randomized subjects, there was an option of rescue treatment with Rebif® for 1 year beginning with the first injection of Rebif®).

Time frame:
From the first dose of study drug administration up to Week 24
Reported as:
Number · Subjects
Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Injection Site Reactions, Infections, and Malignancies by Severity
SubjectsAtacicept 25 mg (With Loading)Atacicept 75 mg (With Loading)Atacicept 150 mg (With Loading)Atacicept 150 mg (Without Loading)
Mild TEAEs58813
Moderate TEAEs2464
Severe TEAEs0001
Mild serious TEAEs0000
Moderate serious TEAEs0100
Severe serious TEAEs0000
Mild injection site reaction2255
Moderate injection site reaction0002
Severe injection site reaction0000
Mild infections1246
Moderate infections0120
Severe infections0000
Mild malignancies0000
Moderate malignancies1000
Severe malignancies0000
PrimaryChange From Baseline in Vital Signs: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

Blood pressure (systolic and diastolic) was measured after at least 3 minutes resting, with the subject in the seated position.

Time frame:
Baseline, Week 2, 4, 8, 12, 16, 20, 24 and 36
Reported as:
Mean · millimeter of mercury (mmHg)
Change From Baseline in Vital Signs: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
millimeter of mercury (mmHg)Atacicept 25 mg (With Loading)Atacicept 75 mg (With Loading)Atacicept 150 mg (With Loading)Atacicept 150 mg (Without Loading)
SBP: Week 2 (n = 13, 16, 14, 20)2.6 ± 8.3-3.0 ± 9.5-1.2 ± 10.7-0.2 ± 9.8
SBP: Week 4 (n = 15, 14, 12, 21)2.1 ± 7.9-2.4 ± 13.7-5.1 ± 12.6-0.1 ± 9.9
SBP: Week 8 (n = 13, 11, 12, 16)0.8 ± 10.5-2.1 ± 12.0-1.1 ± 12.50.4 ± 11.0
SBP: Week 12 (n = 11, 12, 8, 16)3.0 ± 11.7-5.8 ± 15.3-3.4 ± 10.2-0.9 ± 11.3
SBP: Week 16 (n=7, 9, 6, 12)5.9 ± 13.4-9.0 ± 18.6-2.0 ± 12.2-2.3 ± 10.0
SBP: Week 20 (n=3, 7, 2, 6)2.0 ± 23.1-9.7 ± 14.8-0.5 ± 0.73.3 ± 6.0
SBP: Week 24 (n=2, 4, 1, 6)5.0 ± 7.1-5.0 ± 4.110.0 ± NA-5.3 ± 7.7
SBP: Week 36 (n=0, 1, 0, 0)NA ± NA-18.0 ± NANA ± NANA ± NA
DBP: Week 2 (n=15, 13, 14, 21)-2.1 ± 8.2-1.9 ± 8.4-3.6 ± 10.60.3 ± 8.6
DBP: Week 4 (n=15, 14, 12, 21)-0.5 ± 9.0-0.4 ± 8.7-5.1 ± 9.20.1 ± 7.7
DBP: Week 8 (n=13, 11, 12, 16)-2.8 ± 7.7-1.6 ± 8.7-5.9 ± 10.20.1 ± 11.0
DBP: Week 12 (n=11, 12, 8, 16)-3.8 ± 11.1-4.8 ± 8.1-3.5 ± 9.9-2.4 ± 10.3
DBP: Week 16 (n=7, 9, 6, 12)-1.6 ± 14.2-2.9 ± 9.0-2.3 ± 4.2-1.6 ± 7.7
DBP: Week 20 (n=3, 7, 2, 6)-2.0 ± 17.1-4.4 ± 6.02.0 ± 4.23.7 ± 6.3
DBP: Week 24 (n=2, 4, 1, 6)0.0 ± 0.0-6.3 ± 2.50.0 ± NA-1.0 ± 9.8
DBP: Week 36 (n=0, 1, 0, 0)NA ± NA-8.0 ± NANA ± NANA ± NA
PrimaryChange From Baseline in Vital Signs: Pulse Rate
Time frame:
Baseline, Week 2, 4, 8, 12, 16, 20, 24 and 36
Reported as:
Mean · beats per minute (beats/min)
Change From Baseline in Vital Signs: Pulse Rate
beats per minute (beats/min)Atacicept 25 mg (With Loading)Atacicept 75 mg (With Loading)Atacicept 150 mg (With Loading)Atacicept 150 mg (Without Loading)
Week 2 (n=15, 13, 14, 21)-2.1 ± 5.1-3.5 ± 5.5-3.8 ± 10.43.6 ± 11.4
Week 4 (n=15, 14, 12, 21)0.6 ± 8.7-0.6 ± 9.20.7 ± 8.22.0 ± 8.0
Week 8 (n=13, 11, 12, 16)-1.7 ± 9.2-3.4 ± 9.11.3 ± 8.74.4 ± 12.4
Week 12 (n=11, 12, 8, 16)-0.5 ± 6.20.7 ± 9.5-1.5 ± 8.94.5 ± 9.5
Week 16 (n=7, 9, 6, 12)3.9 ± 4.71.1 ± 10.5-0.2 ± 4.83.8 ± 9.1
Week 20 (n=3, 7, 2, 6)-0.3 ± 2.13.9 ± 8.3-5.0 ± 9.911.0 ± 8.8
Week 24 (n=2, 4, 1, 6)2.5 ± 0.7-5.3 ± 9.4-22.0 ± NA9.0 ± 5.3
Week 36 (n=0, 1, 0, 0)NA ± NA7.0 ± NANA ± NANA ± NA
PrimaryChange From Baseline in Vital Signs: Temperature
Time frame:
Baseline, Week 2, 4, 8, 12, 16, 20, 24 and 36
Reported as:
Mean · Degree Celsius
Change From Baseline in Vital Signs: Temperature
Degree CelsiusAtacicept 25 mg (With Loading)Atacicept 75 mg (With Loading)Atacicept 150 mg (With Loading)Atacicept 150 mg (Without Loading)
Week 2 (n=15, 13, 14, 21)-0.09 ± 0.270.09 ± 0.270.03 ± 0.21-0.07 ± 0.36
Week 4 (n=15, 14, 12, 21)-0.03 ± 0.240.05 ± 0.420.03 ± 0.24-0.12 ± 0.31
Week 8 (n=13, 11, 12, 16)-0.03 ± 0.400.05 ± 0.100.03 ± 0.28-0.14 ± 0.25
Week 12 (n=11, 12, 8, 16)0.02 ± 0.190.08 ± 0.360.09 ± 0.57-0.15 ± 0.34
Week 16 (n=7, 9, 6, 12)-0.10 ± 0.210.17 ± 0.35-0.05 ± 0.230.01 ± 0.42
Week 20 (n=3, 7, 2, 6)-0.37 ± 0.350.16 ± 0.56-0.25 ± 0.07-0.08 ± 0.45
Week 24 (n=2, 4, 1, 6)0.05 ± 0.070.30 ± 0.590.00 ± NA-0.07 ± 0.26
Week 36 (n=0, 1, 0, 0)NA ± NA0.70 ± NANA ± NANA ± NA
PrimaryChange From Baseline in Electrocardiogram (ECGs)
Time frame:
Baseline, Week 12 and 36

No measurements were reported for this outcome.

PrimaryNumber of Subjects With Worsened Post Baseline Shift in Immunoglobulin A (IgA), IgG and IgM Levels

Number of subjects with shifts from normal Grade (Grade 0) at Baseline to worse value at post-baseline (Grade 1 to Grade 4) according to the following criteria: IgA Grade 0: greater than or equal to (\>=) lower limit normal (LLN) 0.7 gram per liter (g/L); Grade 1: less than (\<) LLN - 0.5 g/L, Grade 2: \<0.5g/L -0.3 g/L, Grade 3: \<0.3 g/L -0.1 g/L, Grade 4: \< 0.1 g/L; IgG Grade 0: \>= LLN (7 g/L), Grade 1: \< LLN - 5 g/L, Grade 2: \<5g/L -4 g/L, Grade 3: \<4 g/L -3 g/L and Grade 4: \< 3 g/L; IgM Grade 0: \>= LLN (0.4 g/L), Grade 1: \< LLN - 0.3 g/L, Grade 2: \<0.3 g/L -0.2 g/L, Grade 3: \<0.2 g/L -0.1 g/L, and Grade 4: \< 0.1 g/L are presented in this outcome measure.

Time frame:
Baseline up to Week 36
Reported as:
Number · Subjects
Number of Subjects With Worsened Post Baseline Shift in Immunoglobulin A (IgA), IgG and IgM Levels
SubjectsAtacicept 25 mg (With Loading)Atacicept 75 mg (With Loading)Atacicept 150 mg (With Loading)Atacicept 150 mg (Without Loading)
IgA13109
IgG48125
IgM76147
SecondaryNumber of Subjects With Clinical Attacks/Relapses

A clinical attack/relapse was defined as the fulfillment of all the following criteria: 1. Neurological abnormality, either newly appearing or re-appearing, with abnormality specified by both i) neurological abnormality separated by at least 30 days from onset of a preceding clinical event, and ii) neurological abnormality lasting for at least 24 hours. 2. Absence of fever or known infection (fever with temperature (axillary, orally, or intra-auriculary) \> 37.5°C/99.5 °Fahrenheit). 3. Objective neurological impairment, correlating with the subject's reported symptoms, defined as either i) increase in at least 1 of the functional systems of the Expanded Disability Status Scale (EDSS), or ii) increase of the total EDSS score. EDSS overall score ranging from 0 (normal) to 10 (death due to MS) was calculated.

Time frame:
Baseline up to Week 24
Reported as:
Number · Subjects
Number of Subjects With Clinical Attacks/Relapses
SubjectsAtacicept 25 mg (With Loading)Atacicept 75 mg (With Loading)Atacicept 150 mg (With Loading)Atacicept 150 mg (Without Loading)
No Relapse16161521
1 Relapse0321
2 Relapse0000
3 Relapse0000
Greater than or equal to (>=) 4 Relapse0000
SecondaryChange From Baseline in Expanded Disability Status Scale (EDSS) Scores at Week 12

EDSS is an ordinal scale in half-point increments that qualifies disability in participants with multiple sclerosis (MS). It assesses the 8 functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder, cerebral and other) as well as ambulation. EDSS overall score ranging from 0 (normal) to 10 (death due to MS) was calculated.

Time frame:
Baseline, Week 12
Reported as:
Mean · Units on a scale
Change From Baseline in Expanded Disability Status Scale (EDSS) Scores at Week 12
Units on a scaleAtacicept 25 mg (With Loading)Atacicept 75 mg (With Loading)Atacicept 150 mg (With Loading)Atacicept 150 mg (Without Loading)
Change From Baseline in Expanded Disability Status Scale (EDSS) Scores at Week 120.09 ± 0.580.04 ± 0.970.50 ± 0.85-0.06 ± 0.75
SecondaryChange in Multiple Sclerosis Functional Composite (MSFC) Score at Week 12

The MSFC is a multidimensional clinical outcome measure which consists of three sub-tests; Timed 25-Foot Walk, 9-Hole Peg Test and Paced Auditory Serial Addition Test-3(PASAT-3). The Timed 25-Foot Walk is a quantitative measure of lower extremity function. The 9-Hole Peg Test is a quantitative measure of upper extremity (arm and hand) function. The PASAT is a measure of cognitive function that specifically assesses auditory information processing speed and flexibility, as well as calculation ability. Standardized results (Z-scores) of these sub-tests and the overall MSFC Z-score as an average of these three Z-scores was calculated. Higher Z-scores reflect better neurological function and a positive change from baseline indicates improvement. An increase in score indicates an improvement (range -3 to +3).

Time frame:
Week 12
Reported as:
Mean · z-score
Change in Multiple Sclerosis Functional Composite (MSFC) Score at Week 12
z-scoreAtacicept 25 mg (With Loading)Atacicept 75 mg (With Loading)Atacicept 150 mg (With Loading)Atacicept 150 mg (Without Loading)
Change in Multiple Sclerosis Functional Composite (MSFC) Score at Week 120.21 ± 0.400.04 ± 0.47-0.01 ± 0.240.07 ± 0.34
SecondaryMagnetic Resonance Imaging (MRI) Parameters: Number of T1 Gadolinium (Gd)-Enhancing Lesions Per Subject
Time frame:
Baseline, Week 12 and 24
Reported as:
Mean · Number of lesions per subject
Magnetic Resonance Imaging (MRI) Parameters: Number of T1 Gadolinium (Gd)-Enhancing Lesions Per Subject
Number of lesions per subjectAtacicept 25 mg (With Loading)Atacicept 75 mg (With Loading)Atacicept 150 mg (With Loading)Atacicept 150 mg (Without Loading)
Baseline (n=16, 19, 17, 22)1.1 ± 2.22.3 ± 5.00.8 ± 1.40.9 ± 1.4
Week 12 (n=11, 11, 7, 15)0.27 ± 0.470.64 ± 1.291.00 ± 1.152.27 ± 7.16
Week 24 (n=2, 3, 1, 6)0.00 ± 0.002.00 ± 2.000.00 ± 0.000.83 ± 0.75
SecondaryMagnetic Resonance Imaging (MRI) Parameters: Volume of T2 Lesions (New or Enlarging T2 Lesions) Per Subject
Time frame:
Baseline, Week 12 and Week 24
Reported as:
Mean · Cubic millimeter
Magnetic Resonance Imaging (MRI) Parameters: Volume of T2 Lesions (New or Enlarging T2 Lesions) Per Subject
Cubic millimeterAtacicept 25 mg (With Loading)Atacicept 75 mg (With Loading)Atacicept 150 mg (With Loading)Atacicept 150 mg (Without Loading)
Baseline (n=16, 19, 17, 22)4792.76 ± 3152.568196.59 ± 8888.746158.04 ± 7945.595868.84 ± 7170.81
Week 12 (n=11, 11, 7, 15)5604.42 ± 5154.527634.89 ± 6340.194934.03 ± 4802.985365.63 ± 7445.87
Week 24 (n=2, 3, 1, 6)1699.60 ± 586.766814.60 ± 6643.001931.40 ± 0.005541.80 ± 5614.73
SecondaryConcentrations of Free and Total Atacicept
Time frame:
Baseline and Week 12

No measurements were reported for this outcome.

SecondaryFree B-Lymphocyte Stimulator (BLyS) and Free A Proliferation-Inducing Ligand (APRIL) Serum Concentrations.

Levels of free APRIL and free BLyS: Free APRIL serum samples were to be analyzed by using a validated enzyme-linked immunosorbent assay (ELISA) with limits of detection of 0.3125 nanogram per milliliter (ng/mL) for free APRIL and free BlyS serum samples were analysed using a validated ELISA with limits of detection of 1.56 ng/mL.

Time frame:
Baseline, Week 12 and 36

No measurements were reported for this outcome.

SecondaryPharmacogenetics/Pharmacogenomics Analysis

Gene expression profiling and gene polymorphism identification were to be used to identify putative markers for response to treatment. * Genome-wide gene polymorphism characterization by genome-wide scan. * Targeted gene polymorphism identification of B-Lymphocyte Stimulator (BLyS) , APRIL, (receptor for B cell activating factor of the tumor necrosis factor \[TNF\] family) BAFF-R, (Transmembrane Activator) TACI and (B Cell Maturation Antigen) BCMA and HLA-DRB1 by direct genotyping or sequencing .

Time frame:
Day 1 and Week 36

No measurements were reported for this outcome.

PrimaryNumber of Subjects With Positive Neutralizing Antibody (NAb)
Time frame:
Baseline, Week 12 and 36

No measurements were reported for this outcome.

Adverse events

Collected over From the first dose of study drug administration up to Week 24. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Atacicept 25 mg (With Loading)—0/16 (0%)6/16 (37.5%)
Atacicept 75 mg (With Loading)—1/17 (5.9%)9/17 (52.9%)
Atacicept 150 mg (With Loading)—0/15 (0%)8/15 (53.3%)
Atacicept 150 mg (Without Loading)—0/22 (0%)12/22 (54.5%)
Most frequent serious events
Most frequent serious events
EventAtacicept 25 mg (With Loading)Atacicept 75 mg (With Loading)Atacicept 150 mg (With Loading)Atacicept 150 mg (Without Loading)
Peripheral EdemaGeneral disorders0/161/170/150/22
Most frequent other events
Showing 10 of 55
Most frequent other events
EventAtacicept 25 mg (With Loading)Atacicept 75 mg (With Loading)Atacicept 150 mg (With Loading)Atacicept 150 mg (Without Loading)
Injection site reactionGeneral disorders2/162/175/157/22
NasopharyngitisInfections and infestations0/161/173/152/22
HeadacheNervous system disorders0/163/171/152/22
ArthralgiaMusculoskeletal and connective tissue disorders0/160/172/150/22
FatigueGeneral disorders0/162/170/150/22
Acute sinusitisInfections and infestations0/160/171/150/22
Acute tonsillitisInfections and infestations0/160/171/150/22
Herpes zosterInfections and infestations0/160/171/150/22
RhinitisInfections and infestations0/160/171/150/22
DizzinessNervous system disorders0/161/171/150/22

Baseline characteristics

Intent-to-treat (ITT) population included all randomized subjects.

Age, Continuous
Age, Continuous(years)Atacicept 25 mg (With Loading)Atacicept 75 mg (With Loading)Atacicept 150 mg (With Loading)Atacicept 150 mg (Without Loading)Total
Mean39.4 ± 8.436.8 ± 9.137.4 ± 11.234.4 ± 8.636.8 ± 9.3
Sex: Female, Male
Sex: Female, Male(Participants)Atacicept 25 mg (With Loading)Atacicept 75 mg (With Loading)Atacicept 150 mg (With Loading)Atacicept 150 mg (Without Loading)Total
Female81281644
Male879630
08

Study locations

48 sites
  • Research Site
    Phoenix, Arizona, United States
  • Research Site
    Northbrook, Illinois, United States
  • Research Site
    East Lansing, Michigan, United States
  • Research Site
    Cleveland,, Ohio, United States
  • Research Site
    Cleveland, Ohio, United States
  • Research Site
    Philadelphia, Pennsylvania, United States
  • Research Site
    Nashville, Tennessee, United States
  • Research Site
    Box Hill VIC, Australia
  • Research Site
    Fitzroy, Australia
  • Research Site
    New Lambton, Australia
  • Research Site
    Woodville, Australia
  • Research Site
    Diepenbeek, Belgium
  • Research Site
    Sijsele, Belgium
  • Research Site
    Calgary, Alberta, Canada
  • Research Site
    Ottawa, Ontario, Canada
  • Research Site
    Brno, Czech Republic
  • Research Site
    Hradec Králové, Czech Republic
  • Research Site
    Caen, France
  • Research Site
    Saint-Herblain, France
  • Research Site
    Bochum, Germany
  • Research Site
    Düsseldorf, Germany
  • Research Site
    Beyrouth, Lebanon
  • Research Site
    Kaunas, Lithuania
  • Research Site
    Breda, Netherlands
  • Research Site
    Nieuwegein, Netherlands
  • Research Site
    Rotterdam, Netherlands
  • Research Site
    Winston Salem, New Caledonia
  • Research Site
    Ekaterinburg, Russian Federation
  • Research Site
    Moscow, Russian Federation
  • Research Site
    Novosibirsk, Russian Federation
  • Research Site
    Saint Petersburg, Russian Federation
  • Research Site
    Samara, Russian Federation
  • Research Site
    Vladimir, Russian Federation
  • Research Site
    Yaroslavl, Russian Federation
  • Research Site
    Barcelona, Spain
  • Research Site
    Madrid, Spain
  • Research Site
    Malaga, Spain
  • Research Site
    Stockholm, Sweden
  • Research Site
    Basel, Switzerland
  • Research Site
    Innsbruck, Switzerland
  • Research Site
    Zürich, Switzerland
  • Research Site
    Kharkiv, Ukraine
  • Research Site
    Kyiv, Ukraine
  • Research Site
    Odessa, Ukraine
  • Research Site
    Uzhgorod, Ukraine
  • Research Site
    London, United Kingdom
  • Research Site
    Sheffield, United Kingdom
  • Research Site
    Stoke on Trent, United Kingdom
09

References and documents

Publications

  • Kappos L, Hartung HP, Freedman MS, Boyko A, Radu EW, Mikol DD, Lamarine M, Hyvert Y, Freudensprung U, Plitz T, van Beek J; ATAMS Study Group. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Neurol. 2014 Apr;13(4):353-63. doi: 10.1016/S1474-4422(14)70028-6. Epub 2014 Mar 6. PubMed 24613349 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009, a primary completion of Sep 2009 and a completion of Feb 2011. It does not say whether these dates are actual or estimated.

Results were first posted in May 2016, 6 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2009
First posted
Mar 2, 2009
Start
Mar 2009
Primary completionActual
Sep 2009
CompletionActual
Feb 2011
Results first posted
May 24, 2016
Last update
Mar 20, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00853762
Lead sponsor
EMD Serono
Responsible party
Sponsor
First posted
Mar 2, 2009
Start date
Mar 2009
Primary completion
Sep 2009
Completion
Feb 2011
Results posted
May 24, 2016
Last update
Mar 20, 2017

Study contacts

Daniel Mikol, MD, PhD
study director · EMD Serono

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TACI receptor-IgG Fc fragment fusion protein

Start the discussion